• Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, unblinded the ELM-PC 5 Phase III study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration-resistant prostate cancer that had progressed during or following chemotherapy based on the recommendation of the independent data monitoring committee.